Developing life-saving therapies for blood cancer patients

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need.

ATIR™ is Kiadis Pharma’s lead product in development and enables partially matched stem cells from family members (haploidentical donors) to be used in reconstituting the immune system of blood cancer patients after a bone marrow transplantation without eliciting severe or life threatening Graft-versus-Host-Disease (GvHD).

The Company is currently sponsoring a multi‑center Phase II clinical trial for ATIR™ and is collaborating with renowned centers in Europe and North America.









The Company Fact Sheet provides a valuable insight into where Kiadis Pharma stands today.
It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.


Upcoming Conferences



Phacilitate Cell & Gene Therapy Forum
January 26-28, 2015 - Washington DC, USA

European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
March 22-25, 2015 - Istanbul, Turkey

 



Interview with Denis-Claude Roy, MD



Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, talks about ATIR™ at the 2014 annual meeting of American Society of Hematology





Advanced Therapies Investor Day



Watch the company presentation by Manfred Rüdiger, CEO of Kiadis Pharma, at the Advanced Therapies Investor Day held November 13, 2014 in London, UK